SHANGHAI, China and PALO ALTO, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the management is scheduled to participate in the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015.
"We are extremely pleased to provide an overview of the Company, our 2015 clinical milestones and developments in our immuno-oncology cell therapy platforms to investors who are interested in our growing position as a life sciences leader servicing large unmet medical needs in cancer and degenerative diseases," commented Tony (Bizuo) Liu, Chief Financial Officer of Cellular Biomedicine Group. "We look forward to keeping the market apprised of our previously announced Chimeric Antigen Receptor T cell (CAR-T) Phase I clinical data on CD19 and CD20 and interim Phase IIb data on ReJoinTM human adipose-derived mesenchymal progenitor cell (haMPC) therapy for the treatment of Knee Osteoarthritis."
Presentation times and webcast information will be disseminated at a later date.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 email@example.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 firstname.lastname@example.org
Source:Cellular Biomedicine Group Inc.